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Background:  Smoking,  especially  nicotine  dependence  is associated  with  more  severe  symptoms  of
depression  and  anxiety  disorders.  However,  the mechanisms  underlying  this  association  are  unclear.
We  investigated  the effect  of  brain-derived  neurotrophic  factor  (BDNF)  Val66Met polymorphism  on the
severity  of  depressive  and  anxiety  symptoms  in never-smokers,  former  smokers,  non-dependent,  and
nicotine-dependent  smokers  with  a current  diagnosis  of depression  and/or  anxiety.
Methods:  Patients  with  depressive  or anxiety  disorders  and with  available  BDNF  Val66Met  polymorphism
data  (N =  1271)  were  selected  from  Netherlands  Study  of  Depression  and  Anxiety  (NESDA).  Dependent
variables  were  severity  of  symptoms.  Independent  variables  were  smoking  status  and  BDNF  genotype.
Age,  sex,  education,  recent  negative  life  events,  alcohol  use,  body  mass  index,  and  physical  activity  were
treated  as covariates.
Results: After  controlling  for covariates,  nicotine-dependent  smokers  had more  severe  depressive  symp-
toms  than non-dependent  smokers,  former  and never-smokers.  The  latter  three  groups  did not  differ  in
severity  of depression.  In Val66Val  carriers,  nicotine-dependent  smokers  had  more  severe  symptoms
of  depression  and  anxiety  than  the  other  three  groups,  which  were  comparable  in  symptom  sever-
ity.  In  Met66 carriers,  there  were  no  group  differences  on severity  of  depression  and  anxiety.  Nicotine
66dependence  was  the strongest  predictor  of severity  of symptoms  only  in  Val Val  carriers.
Conclusions:  In patients  with  a current  diagnosis  of depression  or anxiety,  the  relationship  between  nico-
tine  dependence  and  symptom  severity  may  be  moderated  by BDNF  Val66Met.  These  results  suggest
that  inherent  genetic  differences  may  be crucial  for the  worse  behavioral  outcome  of nicotine,  and  that
Val66Val  carriers  may  beneﬁt  most  in  mental  health  from  smoking  cessation.
© 2015 Elsevier  Ireland  Ltd.  All  rights  reserved.. Introduction
Epidemiological and clinical research has provided substantial
vidence of an association of smoking with depression and anx-
ety disorders (Chaiton et al., 2009; Cosci et al., 2010; Morrell
nd Cohen, 2006; Moylan et al., 2013; Zvolensky et al., 2005).
icotine-dependent smokers have relatively high rates and more
∗ Corresponding author: Institute of Psychology, Leiden University, Wasse-
aarseweg 52, 2333 AK Leiden, The Netherlands. Tel.: +31 71 527 6668;
ax: +31 71 527 3619.
E-mail addresses: mjamal@fsw.leidenuniv.nl, mjamal.kam@gmail.com
M.  Jamal).
ttp://dx.doi.org/10.1016/j.drugalcdep.2014.12.032
376-8716/© 2015 Elsevier Ireland Ltd. All rights reserved.severe symptoms of depression and/or anxiety as compared to
non-dependent smokers, former- and never-smokers (Breslau
et al., 1991, 1993; Fergusson et al., 1996; Pedersen and von Soest,
2009; Strong et al., 2010). Twin studies have indicated that the
association between smoking/nicotine dependence and depres-
sion/anxiety can be explained by genetic (Edwards et al., 2011;
Kendler et al., 1993; Korhonen et al., 2007; Lyons et al., 2008;
McCaffery et al., 2008), and/or environmental factors (Edwards
et al., 2011; McCaffery et al., 2008; Reichborn-Kjennerud et al.,
2004). However, the biological mechanisms underlying this asso-
ciation are not yet clear.
Brain-derived neurotrophic factor, (BDNF), an important regu-
latory protein and densely-expressed neurotrophin in the central
and the peripheral nervous system, is a member of the nerve
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rowth factor family (Conner et al., 1997; Leibrock et al., 1989).
he BDNF protein is encoded by the BDNF gene which, in humans,
s located on chromosome 11 (Maisonpierre et al., 1991). The sin-
le nucleotide polymorphism (SNP) rs6265 in BDNF gene results
n an amino acid valine-to-methionine substitution at codon 66
Val66Met) (Bath and Lee, 2006).
The Val66Met  polymorphism in the BDNF gene may  be a
lausible candidate gene polymorphism underlying smoking-
epression/anxiety association. An association of this polymor-
hism has been found with affective disorders, and to some extent,
lso with smoking and other addictive behaviors. For example,
revious research points to the involvement of variation in BDNF
al66Met  polymorphism in the pathophysiology of depression
nd anxiety disorders. Studies using magnetic resonance imag-
ng found that Met66 allele carriers with depression had smaller
ippocampal volumes than Val66Val carriers (Frodl et al., 2007).
maller hippocampal volume is also a general characteristic of
ajor depression (Videbech and Ravnkilde, 2004). A meta-analysis
howed that the polymorphism was associated with major depres-
ive disorder (MDD) only in men, and that the MDD  cases more
ften carried the Met66 allele and were often in the homozygous
et66Met  genotype group (Verhagen et al., 2010). However, ﬁnd-
ngs from two cohorts and a meta-analysis indicated that Val66Met
olymorphism is unlikely to play a role in the genetic suscep-
ibility to depression in a large sample (Chen et al., 2008). One
ossible reason of this lack of association might be the non-clinical
ature of the sample and self-report assessment of depression
Chen et al., 2008). Few studies investigated the relationship of
ombination of gene markers including BDNF Val66Met  polymor-
hism with depression. Though single-loci analyses did not show
vidence of a signiﬁcant positive association of the polymorphism
ith major depression, haplotype analysis of the combination of
arkers including BDNF rs6265 (Anttila et al., 2007; Schumacher
t al., 2005; Zhang et al., 2010) produced signiﬁcant associations
ith major depression. A recent mega-analysis of genome-wide
ssociation studies, however, failed to reveal an important role of
his and other polymorphisms in major depression (Sullivan et al.,
013).
No association of BDNF Val66Met  polymorphism has been found
ith anxiety disorders including generalized anxiety disorder
Surtees et al., 2007), panic disorder (Lam et al., 2004; Otowa et al.,
009; Shimizu et al., 2005) and post-traumatic stress disorder (Lee
t al., 2006) except in one community sample of children and ado-
escents (Tocchetto et al., 2011).
Few studies have examined the relevance of this polymor-
hism with addictive behaviors. For example, heroin-dependent
et66 carriers were more often involved in drug-seeking behav-
ors and more cigarette use than Val66Val homozygotes (Greenwald
t al., 2013). Similarly, Met66 carriers drank more alcohol per week,
ere more anxious to tolerate pressure and stress, and showed
igher anticipatory cortisol response to stress than Val66Val carri-
rs (Colzato et al., 2011). Variation in BDNF Val66Met  polymorphism
ight be involved in smoking in schizophrenic patients (Wang
t al., 2007). In a healthy adult German sample (N = 320), the fre-
uency of the Met66 allele of BDNF gene was higher in current and
ormer smokers than in never-smokers (Lang et al., 2007). How-
ver, another study failed to replicate these ﬁndings (Montag et al.,
008). In a recent study with healthy Chinese male population,
ge at the onset of smoking was associated with BDNF Val66Met
olymorphism such that smokers with the Met66 allele initiated
moking signiﬁcantly earlier than the Val66Val homozygous group
Zhang et al., 2012). Thus, Met66 variant of the BDNF gene seems to
e involved in addictive behaviors, although the number of studies
nd the sample sizes are limited.
Smoking, especially nicotine dependence does appear to affect
ymptom severity in depression and anxiety disorders (Jamal et al.,endence 148 (2015) 150–157 151
2012). However, it is not known whether speciﬁc genes are related
to severe symptoms in nicotine-dependent smokers. It has been
argued that in order to elucidate the underlying molecular mecha-
nisms that may  explain the association between phenotypes (in the
current case, between smoking and symptom severity of depres-
sion/anxiety), gene-by-environment interaction studies may  be
more useful (Duncan et al., 2009), and that, psychiatric disorders
may  only be understood if both genetic and environmental fac-
tors are taken into account in the statistical models (Sullivan et al.,
2013).
The aim of the present study was  to investigate the effect of
BDNF Val66Met  polymorphism on the severity of depressive and
anxiety symptoms in a clinical sample. The sample was  categorized
into never-smokers, former smokers, non-dependent smokers and
nicotine-dependent smokers. We  hypothesized that there would
be an association between BDNF Val66Met  polymorphism, smok-
ing/nicotine dependence, and severity of symptoms of depression
and anxiety, and that, the severity of symptoms in nicotine-
dependent smokers would relate to the genetic make-up of the
smoker. In a previous report, we  found that nicotine-dependent
smokers had more severe symptoms of depression and anxiety dis-
orders than non-dependent smokers, former-, and never-smokers
(Jamal et al., 2012). The current study investigates a possible
involvement of the BDNF gene Val66Met  polymorphism in this asso-
ciation.
2. Methods
2.1. Participants and data
Participants were selected from the Netherlands Study of Depression and Anx-
iety (NESDA), an on-going naturalistic cohort study. NESDA started in September,
2004 and investigates the long-term course and consequences of depression and
anxiety disorders by examining clinical, psychosocial, biological and genetic deter-
minants. At baseline, NESDA consisted of 2981 participants (66.4% females) between
18 and 65 years of age. Participants were recruited from mental health care, primary
care, and the general population in order to represent the entire range of depression
and anxiety disorders. The sample consisted of persons with a current diagnosis of
anxiety and/or depression (57%), persons with a remitted history of the disorders
(21%) and healthy controls (22%). The exclusion criteria were: a primary diagnosis of
a  psychotic disorder, addiction disorder, obsessive–compulsive disorder, or bipolar
disorder, and, not being ﬂuent in Dutch. NESDA protocol was  approved by the Ethi-
cal  Review Board of the VU University Medical Center and the local review boards of
participating centers. All participants provided written informed consent. Further
details on the rationale, objectives, design and sample of NESDA were published
elsewhere (Penninx et al., 2008).
In the present study, we selected participants who had a current (past 6 months)
diagnosis of depressive and/or an anxiety disorder at the baseline assessment and
for  whom information on BDNF genotype was  available (N = 1271).
2.2. Measures
Smoking: Smoking behavior was assessed by a self-report questionnaire that
covered past and current smoking behavior. For example, participants were asked
questions about whether they smoked, their age at which they started smoking, the
number of cigarettes they used to smoke or were currently smoking per day. Those
who stopped smoking were asked about their age at which they quitted. Partici-
pants were classiﬁed into four groups based on their smoking status: never-smokers,
former smokers, non-dependent smokers and nicotine-dependent smokers. Former
smokers were those who stopped smoking, and they were, currently, in abstinence.
The mean number of years since cessation was  4.82 (SD = 9.1). Never-smokers were
those who  had no lifetime history of smoking. Nicotine dependence was assessed
with the Fagerstrom Test for Nicotine Dependence (FTND) (Heatherton et al., 1991).
The reliability and internal consistency of FTND have been shown in previous
research (Pomerleau et al., 1994). The FTND (score range: 0-10) assesses daily smok-
ing rate, the interval between waking up and smoking the ﬁrst cigarette, frequency
of  smoking after waking up, difﬁculty refraining from smoking in places where it
is  forbidden, and despite medical illness, and difﬁculty giving up the ﬁrst cigarette
in  the morning. Current smokers with a score of 4 or higher on the FTND in the
present study were deﬁned as nicotine-dependent smokers (Burling and Burling,
2003; Pedersen and von Soest, 2009).
Cotinine levels: As self-reported data are often subject to recall bias, and can
be misleading, thus, cotinine levels were measured in order to provide more reli-
able, biological veriﬁcation of smoking status. Fasting blood samples of NESDA
participants were collected and kept frozen at −80 ◦C. Cotinine concentrations were
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etermined in the laboratory (Good Biomarker Sciences, Leiden, The Netherlands)
nd  were assessed in blood plasma by solid-phase competitive ELISA (Cotinine
irect ELISA kit, Cat. No. CO096D, Calbiotech, Calif., USA) according to the man-
facturer’s instructions. The detection limit was 1 ng/ml. Intra- and inter-assay
oefﬁcients of variation for values >2 ng/ml were >20 and >15%, respectively. Par-
icipants with cotinine values below the detection limit of 1 ng/ml (N = 30) had their
evel  set at the value of .9 ng/ml.
Psychopathology: The Composite International Diagnostic Interview (CIDI v.2.1)
Wittchen et al., 1991) was used to assess the DSM-IV criteria for anxiety and depres-
ive disorders. The CIDI has high inter-rater reliability, test-retest reliability and
alidity for depressive and anxiety disorders (Wittchen et al., 1991).
Severity of depressive symptoms was assessed by the Inventory of Depressive
ymptomatology (IDS; score range: 0–84), which is a 30-item self-report inventory.
t  has shown high correlations with observer rated scales (Rush et al., 1996). The 21-
tem Beck Anxiety Inventory (BAI; score range: 0–62) was  used to assess severity of
nxiety symptoms (Beck et al., 1988). The symptoms of fear were measured with the
5-item Fear Questionnaire (Marks and Mathews, 1979). We  used two sub-scales
f  the Fear Questionnaire: (i) FQ items for social fear symptoms, and (ii) FQ items
or agoraphobia symptoms (Marks and Mathews, 1979). The sum score of both sub-
cales ranges from 0 to 40. BAI and both subscales of FQ have sufﬁcient internal
onsistency (Beck et al., 1988; Vanzuuren, 1988).
Covariates: The Alcohol Use Disorder Identiﬁcation Test (AUDIT) was  used to
ssess alcohol intake (Babor et al., 1989). The International Physical Activity Ques-
ionnaire (IPAQ) was  used to measure physical activity. IPAQ estimates weekly
nergy expenditure based on daily physical activities (Craig et al., 2003). Past-year
egative life events were assessed with the List of Threatening Events Questionnaire
LTE-Q; Brugha et al., 1985). Body mass index (BMI) was  calculated (kg/m2). Other
ovariates under study were age, sex, and education. These covariates were chosen
ecause of their associations with severity of affective symptoms (Caldwell et al.,
002; Da Silva et al., 2012; Leach et al., 2008; Pillay and Sargent, 1999; Spinhoven
t  al., 2011; Zhao et al., 2009).
Genotyping: Venous blood samples were collected at baseline (between 0830
nd 0930 h) after overnight fasting and DNA was isolated using the FlexiGene DNA
GF3000 kit (Qiagen, Valencia, CA, USA) on an AutoGenFlex 3000 workstation (Auto-
en, Holliston, MA, USA). DNA concentrations were determined using the PicoGreens
sDNA Quantitation kit from Molecular Probes. Genotyping of the participants was
onducted by Perlegen Sciences (Mountain View, CA, USA) using four proprietary,
igh-density oligonucleotide arrays. Detailed description of how genotyping was
erformed has been published elsewhere (Boomsma et al., 2008). To extract the
al66Met polymorphism from the whole genome data, PLINK software (v.1.07;
ttp://pngu.mgh.harvard.edu/∼purcell/plink/) was used. The imputation accuracy
f  rs6265 (Val66Met  polymorphism) was 99.9% (r2hat = 999).
The current sample consists of 65.8% Val66Val and 3.5% Met66Met  homozygotes,
hereas 30.7% were Val66Met  heterozygotes. We  combined the low-frequency
et66Met  with Val66Met  (Colzato et al., 2011) and referred to the group as Met66
arriers..3. Statistical analyses
Preliminary analyses were conducted to ensure no violation of the
ssumptions of univariate and multivariate analysis. The Hardy-Weinberg equi-
ibrium for the BDNF polymorphism was tested using a chi-square test for
able 1
articipants’ characteristics stratiﬁed according to their smoking status.
Socio demographic variables and
health behaviors
Never-smokers
(N = 313)
Former smokers
(N = 394)
Age (mean, SD) 38.7 12.8 45.3 11.8 
Sex  (female) (N, %) 220 70.3 262 66.5 
Education, in years (mean, SD) 12.2 3.2 12.1 3.3 
Negative life events (mean, SD) .9 1.1 .9 1.0 
Alcohol  use (mean, SD) 2.9 3.4 4.8 4.6 
Physical activity (mean, SD)a 3.4 2.9 3.6 3.0 
BMI  (mean, SD) 25.6 5.2 26.4 5.1 
Cotinine (ng/ml) 2.4 14.1 3.5 13.6 
Symptom severity (mean, SD)
Symptoms of depression 13.0 12.2 28.3 11.4 
Symptoms of anxiety 15.3 9.6 15.4 9.4 
Symptoms of social anxiety 15.4 8.9 14.4 8.9 
Symptoms of agoraphobia 8.6 8.8 8.7 8.8 
BDNF  genotype (N, %) 
Val66Val carriers 211 67.4 268 68.0 
Met66 carriers 102 32.6 126 32.0 
a Mean met-minutes (ratio of energy expenditure during activity to energy expenditur
b only signiﬁcant results are shown; NS: never-smokers, FS: former smokers, nD: non-pendence 148 (2015) 150–157
goodness-of-ﬁt. Differences on demographic and clinical characteristics between
the groups stratiﬁed according to their smoking status (never-smokers, former
smokers, non-dependent smokers, and nicotine-dependent smokers) were deter-
mined with one-way between-groups ANOVA and chi-square test for independence.
The association of BDNF Val66Met  polymorphism was ﬁrst examined with smoking
status using chi-square test for independence. Next, the estimates of the main and
the  interaction effects of genotype and smoking status on symptoms of depression
and anxiety disorders were computed with multivariate ANCOVA while controlling
for  the covariates on which the groups differed signiﬁcantly. In order to control for
the potentially confounding inﬂuences of the covariates on the main and the inter-
action effects of the BDNF genotype and smoking status, we entered all the covariate
x  smoking status and the covariate x BDNF gene interaction terms in the same model
that tests the BDNF gene x smoking status interaction term, along with the simple
effects of the covariates (Keller, 2014; Yzerbyt et al., 2004). Signiﬁcant interaction
effects were followed up by univariate ANCOVAs, run separately for Val66Val and
Met66 carriers, while applying the same covariate-entering criteria. Eta squared and
partial eta squared were used as the measures of effect size, and alpha level of .05
was used. Finally, the predictors of symptom severity were examined separately
for Val66Val and Met66 carriers using multiple linear regression analyses. Two  mod-
els were ﬁtted in each regression analysis. In the ﬁrst model, we entered age, sex,
education, past-year negative life events, alcohol intake and BMI, and in the second
model we added nicotine dependence. Thus the estimates provided from the ﬁnal
model included all variables. Analyses were run in PASW (v.19.0) for Windows.
3. Results
No serious violation of the assumptions of univariate and
multivariate tests were found. The genotype distributions did
not deviate signiﬁcantly from the Hardy–Weinberg equilibrium
(p = 3).
3.1. Sample characteristics
Of the 1271 participants, 24.6% were never-smokers, 31.0%
were former smokers, and 44.4% were current smokers. Of the
current smokers, 46.5% were nicotine-dependent. The smoking
groups differed signiﬁcantly with respect to age (F (3, 1267) = 26.1,
2 = 06), education (F (3, 1267) = 12.1, 2 = 03), past-year nega-
tive life events (F (3, 1267) = 6.6, 2 = 02), alcohol intake (F (3,
1252) = 33.8, 2 = 07), BMI  (F (3, 1266) = 5.0, 2 = 01), and cotinine
levels (F (3, 1254) = 344.4, 2 = 45). Signiﬁcant group differences
were also found in symptom severity: depression (F (3, 1252) = 14.0,
2 = 03); anxiety (F (3, 1254) = 19.2, 2 = 04); social anxiety (F (3,
1253) = 3.4, 2 = 01); agoraphobia (F (3, 1254) = 9.7, 2 = 02). No
group differences were found in physical activity, sex distribution,
Current smokers p Value Tukeyb
Non-dependent
(N = 302)
Nicotine-dependent
(N = 262)
38.4 11.9 41.7 10.7 <.001 FS > D > FS & NS
208 68.9 164 62.6 =.226
11.8 3.1 10.7 3.1 <.001 D < all groups
1.0 1.2 1.3 1.4 <.001 D > all groups
6.5 5.5 6.5 6.7 <.001 nD & D > FS > NS
3.9 3.5 3.6 3.6 =.432
24.8 4.8 25.5 5.6 =.002 nD < FS
143.8 171.2 311.3 231.5 <.001 NS & FS < nD < D
28.7 12.4 34.2 12.4 <.001 D > all groups
16.5 10.9 21.0 11.2 <.001 D > all groups
14.6 8.7 16.6 9.6 =.017 D > FS
9.4 9.5 12.4 10.9 <.001 D > all groups
=.179
183 60.6 174 66.4
119 39.4 88 33.6
e at rest) divided by 1000.
dependent, D: nicotine-dependent.
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nd BDNF genotype (ps > 05). See Table 1 for post-hoc comparisons
etween the groups for signiﬁcant associations.
.2. Association of smoking status, BDNF genotype, and severity
f depression and anxiety
No association of smoking status with BDNF genotype was
ound. The four smoking groups did not differ signiﬁcantly in
llele distribution (p > 05). We  also examined allele distribu-
ion by collapsing the four smoking groups into two groups of
urrent smokers (non-dependent and nicotine-dependent) and
on-smokers (former and never-smokers), however, the difference
id not reach signiﬁcance (p > 05).
A multivariate ANCOVA showed a signiﬁcant main effect of
moking status on the symptoms of depression (F (3, 1230) = 3.9,
 = 01, partial 2 = 01), while a non-signiﬁcant main effect on the
ymptoms of anxiety, social anxiety, and agoraphobia (ps > 05).
icotine-dependent smokers had more severe symptoms of
epression than the other three groups (ps < 05) which were not
ifferent signiﬁcantly (ps > 05) in severity of depression (Table 2).
he main effect of BDNF genotype on symptom severity of depres-
ion and anxiety disorders was non-signiﬁcant (ps > 05). The
nteraction effect of BDNF genotype and smoking status was signif-
cant for symptoms of depression (F (3, 1230) = 3.1, p < 05, partial
2 = 01) and anxiety (F (3, 1230) = 2.8, p < 05, partial 2 = 01), while
on-signiﬁcant for symptoms of social anxiety and agoraphobia
ps > 05).
The subsequent univariate ANCOVAs revealed that in Val66Val
arriers, the main effect of smoking status on symptoms of depres-
ion (F (3, 812) = 8.7, p < 001, partial 2 = 03) and general anxiety
F (3, 813) = 5.6, p = 001, partial 2 = 02) was signiﬁcant. Pairwise
omparisons showed that nicotine-dependent smokers had signif-
cantly more severe symptoms of depression and general anxiety
han non-dependent smokers, former smokers, and never-smokers
ps < 05). Never-smokers, former smokers, and non-dependent cur-
ent smokers did not differ signiﬁcantly from each other (ps > 05)
n severity of depressive and anxiety symptoms (Table 2).
In Met66 carriers, the non-signiﬁcant main effect of smoking
tatus on symptoms of depression and general anxiety (ps > 1) sug-
ested that smoking groups carrying Met66 allele did not differ
igniﬁcantly from each other in symptom severity (Table 2).
.3. Predictors of symptom severity
Regression analyses indicated that in Val66Val group, the ﬁrst
odel with age, sex, education, negative life events, alcohol intake,
nd BMI  explained 7.6% of the variance in severity of depres-
ion (p < 001). The second model that added nicotine dependence
ccounted for an additional 5% of the signiﬁcant variance (R2 = .125,
 < 001). In Met66 carriers, only the ﬁrst model with age, sex, edu-
ation, negative life events, alcohol intake, and BMI  explained
igniﬁcant variance (R2 = .07, p < 05).
The same pattern emerged with anxiety severity as the depend-
nt measure. In Val66Val group, the ﬁrst model explained 6.4%
ariance in severity of anxiety (p = 001), and the second model with
icotine dependence accounted for an additional 5% of the signif-
cant variance (R2 = .12, p < 001). In Met66 carriers, only the ﬁrst
odel explained signiﬁcant variance (R2 = .10, p < 01).
Nicotine dependence was the strongest signiﬁcant predictor
f depressive and anxiety symptoms only in Val66Val carriers
Table 3).. Discussion
We  have previously reported that nicotine-dependent smok-
rs had more severe symptoms of depression and anxiety than Ta
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Table 3
Regression of nicotine dependence on the severity of symptoms stratiﬁed according to the BDNF genotype.
Predictors BDNF Val66Val carriers BDNF Met66 carriers
B SE  ˇ p Value B SE  ˇ p Value
Severity of the symptoms of depression
Age −.07 .06 −.07 .21 .01 .07 .01 .87
Sex  .78 1.39 .03 .58 −.03 1.82 .001 .99
Education −.49 .21 −.13 .02* −.67 .27 −.18 .01*
Negative life events .55 .51 .06 .29 .06 .77 .01 .94
Alcohol intake .01 .12 .004 .94 −.04 .17 −.02 .83
BMI  .38 .13 .16 .01* .31 .17 .13 .07
Nicotine dependence 1.11 .26 .24 <.001*** .58 .34 .12 .09
Severity of the symptoms of anxiety
Age −.05 .05 −.05 .33 −.01 .06 −.01 .90
Sex  −.10 1.18 −.004 .93 −1.40 1.56 −.06 .37
Education −.45 .17 −.14 .01* −.90 .23 −.27 <.001***
Negative life events .53 .44 .06 .22 −.26 .67 −.03 .70
Alcohol intake .07 .10 .04 .49 .05 .14 .02 .74
BMI  .20 .11 .10 .08 .21 .14 .11 .14
Nicotine dependence .96 .22 .24 <.001*** .41 .29 .10 .16
*
*
*
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* p < 01.
p < 05.
on-dependent smokers, former-, and never-smokers (Jamal et al.,
012). Here we examined the role of the BDNF Val66Met polymor-
hism in this association.
In the current sample, nicotine-dependent smokers had more
evere symptoms of depression as compared to non-dependent
mokers, former smokers, and never-smokers. No group differ-
nces were found in symptoms of anxiety, social anxiety, and
goraphobia. The BDNF polymorphism had no direct effect on
moking status and on the severity of affective symptoms in the
resent sample. However, we did observe an interaction of smoking
tatus and BDNF polymorphism with the symptoms of depression
nd anxiety. In Val66Val carriers, nicotine-dependent smokers
ad more severe symptoms of depression and anxiety than
on-dependent smokers, former- and never-smokers, whereas the
atter three groups were comparable in symptom severity. In Met66
arriers no differences among the four smoking groups were found
n symptoms of depression and anxiety. We  also found that after
ontrolling for the potential confounding variables, nicotine depen-
ence was the strongest predictor of the symptoms of depression
nd anxiety only in Val66Val homozygotes. These ﬁndings suggest
hat genetic predisposition and nicotine dependence may  act
nterdependently in symptom severity of affective disorders.
These ﬁndings need to be replicated as there is no previous
eport on the interacting effects of BDNF gene and smoking sta-
us on depressive and anxiety symptoms. Most of the previous
iterature is based on association studies that look for a direct
elationship of BDNF Val66Met  polymorphism with depression, or
ith smoking, and most of the studies examined genotype or allele
requencies. In order to elucidate the underlying molecular mech-
nisms through which variation in the BDNF gene may  lead to
everity of symptoms, gene-by-environment interaction studies
ay  be more useful (Duncan et al., 2009; Sullivan et al., 2013).
The observed association might be interpreted in the context of
revious MRI  research which shows that Val66Val genotype is asso-
iated with reduced hippocampal gray matter volumes in healthy
aucasian participants (Pezawas et al., 2004). Further, reduced
ippocampal gray matter volume has also been associated with
ajor depression (Videbech and Ravnkilde, 2004). Thus, it can be
peculated that nicotine-dependent smokers who carry Val66Val
ariant of the BDNF gene may  have reduced hippocampal gray
atter volume and thus may  experience more severe symptoms
han nicotine-dependent Met66 carriers whose brain morphology
ay not be depression-vulnerable. This speculation has beensupported by animal research. In a recent animal model of depres-
sion, nicotine administration exacerbated depressive-like behavior
in inbred Wistar-Kyoto (WKY) rats, which had reduced hippocam-
pal volume but not in the control Wistar rats with comparatively
large hippocampal volume (Tizabi et al., 2010). Research has also
shown greater genotypic variability among WKY  rats compared to
other inbred strains (Will et al., 2003; Zhang-James et al., 2013).
It has been proposed that the differential responses of WKY  and
Wistar rats to nicotine may  reﬂect genetic differences (Tizabi et al.,
2010). Thus, the current ﬁndings suggest that genetic differences
are important determinants to explain worse behavioral outcome
of nicotine in some individuals but not in others. However, this
theory needs to be conﬁrmed in longitudinal research, in particular,
in MRI  and genetic investigations.
This study has some limitations which should be taken into
account. First, we investigated only one polymorphism, therefore it
is likely that differences across the smoking groups could be related
to internalizing outcomes in many ways other than their genotype
at this BDNF variant, and that, other polymorphisms in the BDNF
gene or other genes are likely to be involved. Second, the study is
cross-sectional, so causality cannot be inferred. Finally, our ﬁndings
may  not be generalizable to other ethnic groups.
Strength of our study is the relatively large sample size com-
pared to prior research in this area (though, for a genetic study, it
is still quite small to be able to reliably detect genetic effects). We
investigated patients with a diagnosed psychiatric disorder, unlike
most previous studies that used samples from general population.
The depression and anxiety disorder diagnoses were made accord-
ing to DSM-IV criteria, whereas most previous studies assessed
symptoms using self-report measures. The study sample is ethni-
cally homogenous and we were able to control for a large number
of covariates.
Despite a well-established association between smoking and
depression and anxiety disorders, and the evidence that the
co-variation between smoking and depression/anxiety is due to
genetic factors (e.g., Lyons et al., 2008), the mechanisms underlying
this association have rarely been investigated taking into account
the role of candidate genes. Only few studies have investigated
the interacting effects of genetic predisposition and depressive
symptoms on smoking. The two  short alleles of DRD4 gene are
associated with self-medicating smoking practices in depressed
individuals (Lerman et al., 1998). Similarly, smokers with severe
depressive symptoms were progressing to a higher level of
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moking only if they had DRD2A1 allele (Audrain-McGovern et al.,
004). However, these studies support the notion of smoking as
 self-medicating agent to alleviate depressive symptoms. The
heory, that smoking is a vulnerability factor in depression and
nxiety has recently been investigated in a large population-based
tudy of 53,601 participants, using the rs1051730 single nucleotide
olymorphism variant located in the nicotine acetylcholine recep-
or gene cluster on chromosome 15. A positive association was
ound between smoking and the symptom severity of both anxi-
ty and depression in this population sample. Further, rs1051730
olymorphism was associated with current smoking and with the
umber of cigarettes smoked per day. However, no association
f the polymorphism with the symptom severity of either anxi-
ty or depression was found among smokers. Consequently, the
uthors proposed that smoking was not a causal factor of anxiety
nd depression, and that, the self-medication hypothesis seemed
o be more plausible to explain the association of smoking with
epression or anxiety (Bjorngaard et al., 2013). In line with Bjorn-
aard study, we also found that the BDNF polymorphism was not
ssociated with the symptom severity of depression or anxiety,
nd that, (nicotine-dependent) smoking was associated with the
ymptoms of depression in a dose-dependent fashion. However,
e found no association of smoking with the polymorphism. More-
ver, we did observe an interaction of smoking status and BDNF
olymorphism with depressive and anxiety symptoms. Our results,
herefore, are indicative of the ‘smoking as a vulnerability factor
n depression/anxiety’ theory. We  found a genotype-dependent
ose–response relationship between nicotine dependence and
ymptom severity of depression and anxiety. Though, this theory
ould not be elucidated in the current study because of its cross-
ectional nature, it may  provide a starting point for understanding
he neurobiological links between smoking or nicotine dependence
nd affective disorders. Here, it is worth mentioning that the study
y Bjorngaard et al. was methodologically different from our study
n that we examined symptom severity in a clinical sample that
ulﬁlled DSM criteria for the diagnosis of depression and anxiety.
oreover, we categorized current smokers into non-dependent
nd nicotine-dependent smokers and assessed smoking severity
nicotine dependence) using FTND. In the study by Bjorngaard et al.,
owever, severity of symptoms was assessed using a 14-item Hos-
ital Anxiety and Depression Scale (HADS) in a non-psychiatric
ample from the general population, and smoking severity was
ssessed by a self-report questionnaire.
The results of these two studies suggest that the nature of the
ssociation between smoking and depression/anxiety is a complex
ne, and may  be different in psychiatric and non-psychiatric sam-
le.
This study has clinical implications, for example, Val66Val carri-
rs may  beneﬁt most from smoking cessation or lowering amount
f smoking. It could still be that smoking in this group is a
ailed attempt at self-medication. Thus, future study could focus
n immediate versus longer-term subjective effects of lighting a
igarette in this group. If it turns out that smoking reduces anx-
ety in the short-term, this group may  particularly beneﬁt from
ther interventions that reduce anxiety while they attempt to
uit.
This study also has important implications for future molecular
esearch on smoking–psychopathology association. Given the high
revalence of depression and anxiety in smokers, it is important
o focus on investigating the genetic and biological inﬂuences to
lucidate the mechanisms underlying the association between
moking and affective disorders. Moreover, DSM assessment for
icotine dependence may  be more useful for identifying smok-
rs vulnerable to depression and anxiety (Manley et al., 2009).
nderstanding of genetic inﬂuences on smoking–psychopathology
ssociation may  be signiﬁcant for guiding smoking interventionendence 148 (2015) 150–157 155
programs in identifying smokers, particularly those with nicotine
dependence who are vulnerable to adverse outcomes.
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